Arable Corporation Announces New Technology for Clinical Trial Industry
PALO ALTO, Calif., Oct. 11 /PRNewswire/ -- Arable Corporation (www.arablecorp.com) has announced the launch of Arable Perform to bring unique CTMS technologies to the clinical trial industry. Whereas traditional CTMS systems have been costly and require months to implement, Perform brings CTMS and EDC capabilities without the traditionally high start-up costs.
The Arable Perform platform allows Sponsors or CROs to manage the planning and implementation of multiple trials simultaneously. Perform also provides large Sites with the ability to manage their service delivery to multiple CROs or Sponsors. With Perform's proprietary dashboard, stakeholders and managers are able to view real-time status of trials down to the site or subject visit.
"Our new Arable Perform platform allows us to offer our clients immediate access to clinical trial software with the shortest "Go Live" time in the industry and at a reasonable cost," stated Ary Sarkar, CEO of Arable Corporation. "At Arable, we combine our knowledge of the clinical trial space with our technology partnerships to offer our clients a range of services from trial planning and implementation through regulatory submittal."
Arable brings a suite of services to offer the pharmaceutical and biotech industries. With the addition of the Perform platform, Arable introduces CTMS and EDC software to complement their existing partnerships with GlobalSubmit and Quest Life Sciences.
Arable is announcing a 30 day free trial of their Perform platform to highlight the benefits to clinical organizations. With the economic recovery continuing to affect pharma and biotech R & D budgets, Arable believes that the Perform software will save clinical organizations money and increase time to market. Terms and conditions apply to the free offer.
Arable Corporation combines the right technology with our proven CRO servic